Metabolic Psychiatry · Clinical Guide
Metabolic Psychiatry
Psychiatry is a branch of medicine. Psychiatric illness frequently carries a substantial physical-health burden, psychiatric medications can meaningfully affect metabolic health, and metabolic conditions can influence how a patient thinks, sleeps, and functions. Metabolic psychiatry is the practice of taking that relationship seriously in the care of an individual patient.
Care is provided personally by Christian S. Monsalve, M.D., a board-certified psychiatrist, by telemedicine — available only in jurisdictions where the physician is appropriately licensed.
What This Page Covers
This guide describes how metabolic health is considered within psychiatric practice: the physical-health burden that accompanies serious mental illness, the differing metabolic effects of psychiatric medications, the prevention and management of medication-associated metabolic harm, the role of nutrition, physical activity and sleep, and the current evidentiary standing of ketogenic metabolic therapy. It is written for patients, families, and referring physicians. It is not a diet program.
First Principle
Psychiatry Is Medicine
Psychiatric medicine does not operate in a separate biological universe from the rest of medicine. Brain and body are not independent systems, and the factors that shape a psychiatric presentation may be biological, pharmacological, medical, psychological, behavioural, or contextual — often several at once.
This does not mean that every psychiatric symptom is metabolic, that every psychiatric illness is nutritional, or that lifestyle intervention substitutes for evidence-based treatment. Reductionism in that direction is as unhelpful as ignoring the body altogether.
The responsibility of a psychiatrist is narrower and more demanding than either extreme: to determine which of these factors actually matter for this patient, in what order, and to what degree — and then to act on that judgement.
Scope
Metabolic psychiatry, as practised here, is a way of thinking about the whole patient. It is not a single treatment, a diet protocol, or a replacement for established psychiatric care.
Physical Health Burden
Psychiatric Illness and Physical Health
People living with serious psychiatric illness experience considerably more cardiovascular disease, and die of it more often, than people who do not. This is one of the better-established findings in modern psychiatry, and it is the reason metabolic health belongs inside psychiatric care rather than alongside it.
A large-scale meta-analysis of 92 studies, comparing more than three million patients with severe mental illness against more than 113 million controls, found significantly higher odds of cardiovascular disease after adjustment for confounders, higher odds of coronary heart disease and cerebrovascular disease, and — over a median 8.4 years of follow-up — significantly higher cardiovascular incidence and higher cardiovascular mortality. Elevated body mass index and antipsychotic exposure were among the factors associated with greater incidence.
Several mechanisms plausibly contribute: the illness itself, its effect on sleep, activity and nutrition, the social and economic consequences of chronic psychiatric illness, unequal access to general medical care, and the metabolic effects of some psychiatric medications. These are not mutually exclusive, and separating them in an individual patient is a clinical task rather than a theoretical one.
Psychopharmacology
Psychiatric Medications and Metabolic Health
Psychiatric medications are not metabolically interchangeable. Evidence supports meaningful differences between agents in their effects on weight, lipids, and glucose — which means medication selection, monitoring, prevention, and mitigation are all legitimate clinical levers.
A network meta-analysis of 100 blinded randomised controlled trials, including 25,952 patients treated for schizophrenia, compared 18 antipsychotics and placebo over a median of six weeks. Mean weight change relative to placebo ranged from −0.23 kg for haloperidol to 3.01 kg for clozapine, with a comparable spread across total and LDL cholesterol, triglycerides, and glucose. Higher baseline weight and male sex predicted greater glucose increases.
Network meta-analyses of longer-term antipsychotic treatment, and of antipsychotics and mood stabilisers in bipolar disorder, point in the same direction: the metabolic consequences of treatment differ by agent. None of this makes these medications inappropriate. For many patients they are necessary, and the risk of undertreated psychiatric illness is itself substantial. It does mean that the metabolic cost of a regimen is a clinical variable to be weighed, monitored, and — where possible — reduced.
Evaluation
A Broader Medical Assessment
A psychiatric consultation that takes metabolic health seriously asks a wider set of questions than symptom scores alone. The purpose is not to find a hidden metabolic explanation for every presentation, but to establish what is actually true of this patient’s body before making decisions about their treatment.
Complete medication history, including agents previously trialled, doses, duration, response, and adverse effects
Weight trajectory over time, rather than a single measurement
Glucose regulation, lipids, blood pressure, and where relevant markers of insulin resistance
Thyroid function, and other general medical conditions capable of affecting mood, energy, or cognition
Sleep duration, continuity, and evidence suggesting a primary sleep disorder
Alcohol and other substance use, including patterns the patient may not consider clinically relevant
Physical activity and sedentary time as they actually occur, not as an aspiration
Nutrition, eating pattern, and the practical circumstances that shape both
Existing relationships with primary care and other specialists, and what those physicians are already managing
Nutrition · Activity · Sleep
Nutrition, Physical Activity and Sleep
These are ordinary parts of medical care, and they are frequently neglected in psychiatric practice. They are also frequently overstated. Both errors are worth avoiding.
A meta-analysis of randomised controlled trials of dietary improvement reported reductions in symptoms of depression, with less consistent findings for anxiety. The effects observed were modest, the interventions heterogeneous, and the results should be read as supportive of attention to nutrition rather than as evidence that diet is a primary treatment for depression.
Physical activity has been studied more extensively, and is discussed separately. Sleep sits at the intersection of psychiatric symptoms and metabolic regulation, and disturbed sleep frequently deserves direct clinical attention rather than being treated as a downstream symptom.
One Emerging Intervention
Ketogenic Metabolic Therapy
Ketogenic metabolic therapy is one intervention studied within metabolic psychiatry. It is not the definition of the field, and it is not appropriate for most patients. It is presented here because the literature is developing quickly and patients increasingly ask about it.
A ketogenic diet is a therapeutic dietary intervention, originally established in the management of drug-resistant epilepsy, that shifts the body’s primary fuel from glucose toward ketone bodies. Researchers have proposed several mechanisms by which this might affect psychiatric symptoms — including changes in brain energy metabolism, neurotransmitter balance, and inflammation. These proposals are biologically plausible and remain unproven as clinical explanations.
When it is considered at all, it is considered as a medically supervised intervention with defined monitoring, alongside — not instead of — established psychiatric treatment. It carries real risks, including effects on lithium levels, hypoglycaemia in patients on insulin or sulfonylureas, electrolyte disturbance, and lipid changes. It is not appropriate for patients with a history of eating disorder, certain metabolic conditions, in pregnancy, or where supervision cannot be arranged.
Important
Verigrate does not offer ketogenic therapy as a standalone service, and does not present it as a treatment for psychiatric illness. Where it is discussed, it is discussed as one option under active investigation, requiring medical supervision and coordination with the patient’s other physicians.
Evidence Hierarchy
What the Evidence Actually Shows
Not everything discussed under the heading of metabolic psychiatry rests on the same quality of evidence. Distinguishing what is established from what is emerging, preliminary, or genuinely uncertain is part of practising responsibly — and part of what a patient or referring physician is entitled to know.
Established Evidence
Guidelines, high-quality meta-analyses, replicated randomized evidence, and mature medical principles.
Serious mental illness is associated with substantially increased cardiovascular disease and cardiovascular mortality. Antipsychotics differ meaningfully from one another in their effects on weight, lipids, and glucose. Baseline and ongoing metabolic monitoring is standard care. Metformin has guideline and consensus support for the prevention of antipsychotic-induced weight gain in appropriate patients.
Emerging Evidence
Promising controlled trials, or a developing clinical literature not yet mature enough to support definitive conclusions.
Randomized trials of ketogenic dietary intervention have now been conducted in treatment-resistant depression and in psychosis, and a systematic review and meta-analysis of ketogenic diets in depression and anxiety has been published. This is a genuine advance over the case-report literature. The trials remain few, comparatively small, and heterogeneous in design and duration, and the distinction between randomized phases and open extension periods matters when interpreting reported results. Dietary improvement more broadly has shown modest benefit for depressive symptoms in randomized trials.
Preliminary Evidence
Small pilot studies, open-label trials, retrospective analyses, case series, and feasibility data.
Much of the ketogenic psychiatry literature remains at this level: single-arm pilot studies in bipolar disorder and schizophrenia, feasibility and safety pilots, a retrospective analysis of 31 inpatients with refractory illness, and small case series — including a three-patient series in obsessive-compulsive disorder. These reports establish that the intervention can be delivered and tolerated in selected supervised patients. They do not establish efficacy.
Clinical Uncertainty
Active research questions, or biologically plausible hypotheses for which clinical conclusions remain unsettled.
It remains uncertain whether psychiatric improvement observed with metabolic intervention is attributable to the metabolic change itself, to weight loss, to the intensity of clinical contact involved, or to other factors. Durability beyond the study period, real-world adherence, long-term safety, and which patients are most likely to benefit are all open questions. Published expert consensus exists on implementation and safety, but expert consensus is not randomized evidence and should not be represented as such.
Safety
Safety and Medical Monitoring
Any metabolic intervention undertaken alongside psychiatric medication requires monitoring. The interactions are not hypothetical.
Lithium levels can shift with changes in fluid, sodium, and carbohydrate intake, and require closer monitoring
Patients taking insulin or sulfonylureas are at risk of hypoglycaemia and require prescriber coordination before any change
Antihypertensive regimens may need adjustment as weight and fluid balance change
Electrolytes, renal function, and lipids warrant baseline measurement and periodic review
Psychiatric stability is monitored throughout; a metabolic intervention is never a reason to withdraw effective psychiatric treatment unilaterally
Appropriateness
Who May — and May Not — Be an Appropriate Candidate
Most patients who consult Verigrate about metabolic psychiatry are not candidates for a metabolic intervention. They are candidates for a careful reconsideration of their medication regimen and their general medical health.
Consultation may be useful when
Significant weight, glucose, or lipid change has followed a psychiatric medication
A complex regimen has accumulated without clear review of its metabolic cost
Psychiatric and general medical care have not been considered together
A patient or family is seeking an informed physician view on metabolic approaches they have read about
Consultation is unlikely to be appropriate when
There is an active or historical eating disorder
The patient is pregnant or planning pregnancy
Acute psychiatric instability requires stabilisation first
The expectation is that a dietary intervention will replace established psychiatric treatment
Appropriate medical supervision and monitoring cannot be arranged
Collaboration
Coordination With Primary Care, Endocrinology, Nutrition and Cardiology
Metabolic questions in psychiatry are rarely a psychiatrist’s alone. Where a patient has an established relationship with a primary care physician, endocrinologist, cardiologist, or registered dietitian, that relationship is the foundation to build on rather than something to work around. With the patient’s authorisation, Dr. Monsalve communicates directly with treating physicians, provides written psychiatric reasoning where it is useful, and returns the patient to the treating team when the consultative question has been answered.
Clinical Perspective
Ketosis is not the goal. Neither is a laboratory value, a weight, nor a symptom score. The end of medicine is health — and health matters because it supports a person’s capacity to think, work, sustain relationships, and act on their own aims.
Metabolic interventions, medications, dose reductions, and monitoring are all instruments. Each is justified only insofar as it advances the health of this particular patient, consistent with the evidence, sound medical judgement, safety, and the patient’s own circumstances and goals. That test is what distinguishes clinical reasoning from enthusiasm.
Common Questions
Questions Patients and Physicians Ask
Is metabolic psychiatry the same thing as the ketogenic diet?
No. Metabolic psychiatry describes attention to metabolic and general medical health within psychiatric care. Most of that work is conventional: choosing medications with their metabolic profile in mind, monitoring appropriately, preventing and managing medication-associated harm, and coordinating with the patient’s other physicians. Ketogenic metabolic therapy is one investigational intervention within that broader field.
Will I be asked to stop my psychiatric medication?
No. Deprescribing is not an aim in itself, and no medication is reduced simply because reduction is possible. Where a regimen appears to be carrying a metabolic cost that is no longer justified by benefit, that is discussed openly and, if change is indicated, approached gradually and with monitoring.
Does Verigrate provide nutritional or dietitian services?
No. This is a psychiatric practice. Where nutritional care is indicated, it is coordinated with a registered dietitian or the patient’s primary care physician rather than delivered here.
Is the evidence for ketogenic therapy in psychiatry strong?
It is developing. Randomized trials have now been published in treatment-resistant depression and in psychosis, which represents real progress beyond the earlier pilot and case-series literature. The trials remain few and comparatively small, and important questions about durability, adherence, mechanism, and patient selection are unresolved. It would be inaccurate to describe the evidence as established.
How is this consultation provided?
By telemedicine, personally by Dr. Monsalve, for patients located in states where he is licensed or otherwise legally authorised to provide care. Availability is listed on the States Served page.
References
Selected Clinical References
A selection of the primary literature informing this page, ordered approximately by strength of evidence. Study design is stated so that each finding can be weighed appropriately.
Meta-analysis · World Psychiatry, 2017 · doi:10.1002/wps.20420
Network meta-analysis of randomized controlled trials · Lancet Psychiatry, 2020 · doi:10.1016/S2215-0366(19)30416-X
Network meta-analysis of randomized controlled trials · World Psychiatry, 2023 · doi:10.1002/wps.21036
Network meta-analysis of randomized controlled trials · EClinicalMedicine, 2024 · doi:10.1016/j.eclinm.2024.102581
Guideline development and consensus validation · Schizophrenia Bulletin · doi:10.1093/schbul/sbae205
Meta-analysis of randomized controlled trials · Psychosomatic Medicine, 2019 · doi:10.1097/PSY.0000000000000673
Randomized clinical trial · JAMA Psychiatry, 2026 · doi:10.1001/jamapsychiatry.2025.4431
Systematic review and meta-analysis · JAMA Psychiatry, 2026 · doi:10.1001/jamapsychiatry.2025.3261
Single-arm pilot trial · Psychiatry Research, 2024 · doi:10.1016/j.psychres.2024.115866
Expert consensus (modified Delphi) — implementation and safety, not efficacy · Frontiers in Nutrition, 2026 · doi:10.3389/fnut.2026.1749406
Authored and medically reviewed by Christian S. Monsalve, M.D. — Board-Certified Psychiatrist, Founder & Medical Director, Verigrate Health.
This page reflects a physician-developed synthesis of the peer-reviewed literature concerning metabolic health in psychiatric practice. Where evidence is emerging, preliminary, or unsettled, it is labelled as such rather than presented as established.
This content is provided for educational purposes only and does not replace individualized medical evaluation or treatment. Decisions regarding psychiatric medication, metabolic intervention, or dietary change should be made in consultation with a qualified physician who can consider the patient’s full medical history and circumstances.
Clinical Summary
Metabolic psychiatry, practised carefully, is mostly good general medicine applied inside psychiatry — and only occasionally something newer.
If a psychiatric regimen appears to be carrying an unexamined metabolic cost, or a complex presentation has never been considered alongside the patient’s physical health, a focused consultation is a reasonable place to begin. Care is available by telemedicine only where Dr. Monsalve is appropriately licensed.